Dr Massarelli talks to ecancer about her phase II study of autologous tumour infiltrating lymphocytes cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC), currently still enrolling.
Dr Massarelli starts by describing how the study focuses on using tumour infiltrating lymphocytes (TIL) extracted directly from the patient to attempt to successfully treat mNSCLCr, after previous successful uses in melanoma treatment.
She goes on to explain the enrolment parameters for the clinical trial followed by the methodology used, stating that a tumour sample is taken from patient where the TIL will be extracted, reinvigorated and expanded, to then be re-injected into the patient. The manufacturing of LN-145 will take up to 3 weeks, which is typically faster than other T-cell therapy trials. One of the advantages of this is that patients do not need to be profiled for Human Leukocyte Antigens.
To conclude, Dr Massarelli reiterates the importance of T-cell therapy for patients with driver mutations with mNSCLC who have progressed after cytotoxic chemotherapy plus immune checkpoint inhibitors as these patients have a very limited number of opportunities.
This is currently an open trial and Dr Massarelli urges fellow doctors in the area with suitable patients to get in touch to be considered for the trial.
Her email can be found in the video.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.